Sarepta to buy Myonexus to expand muscular dystrophy therapy portfolio
Category: #health  By Mateen Dalal  Date: 2019-02-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sarepta to buy Myonexus to expand muscular dystrophy therapy portfolio

Sarepta Therapeutics has recently confirmed that it is planning to acquire Myonexus Therapeutics in a $165 million deal, by exercising a purchase option that was part of a gene therapy partnership commenced by the firms in the previous year.

The transaction is aimed at broadening the pipeline of Sarepta with the five Myonexus candidates. Supposedly, these five candidates all use the same gene therapy platform that was licensed from Nationwide Children’s Hospital, designed for delivering treatment to skeletal and cardiac muscle robustly and systematically, without crossing the blood-brain barrier promiscuously.

According to Sarepta, all the five gene therapy candidates have been developed for offering the first-ever corrective therapy for five distinctive Limb-girdle muscular dystrophy (LGMD) forms, which are LGMD2B, LGMD2C, LGMD2D, LGMD2E, and LGMD2L.

The firm informed that three of the five programs are presently in clinical stages. MYO-101 from Myonexus, designed for LGMD2E, is the furthest in development and is aimed at restoring the dystrophin-related protein complex by transferring a gene which codes for and restores beta-sarcoglycan protein.

Myonexus, in November 2018, had unveiled the launch of a first-in-human, Phase I/IIa trial for MYO-101. It was a placebo-controlled study designed for evaluating a single infusion of MYO-101 intravenously among children aged between 4 and 15 years and having LGMD2E, with considerable symptoms of the disease.  

Apparently, the study was designed to assess up to two levels of dosage of the gene therapy candidate in two cohorts among nine patients, with their baseline measurements established on the basis of a recruitment study.

Doug Ingram, president and CEO of Sarepta, said acquiring Myonexus will enable the company to rapidly move and find solutions for LGMD patients, while continuing to develop and validate its gene therapy engine. The five gene therapies for LGMD under development are an ideal fit for the mission of Sarepta, to develop therapies having the potential to rescue patient lives from serious and life-limiting rare genetic disorders, Ingram added.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Health insurer Alan acquires Jour to enter the mental health market
Health insurer Alan acquires Jour to enter the mental health market
By Mateen Dalal

Alan, a health insurance startup based in France, has acquired American digital behavioral health firm, Jour for $20 million. The acquisition has assisted the French health insurer to launch its new digital health service, Alan Mind, helping it ...

WAVE Electronics adds CYNC™ Smart Home solutions to its portfolio
WAVE Electronics adds CYNC™ Smart Home solutions to its portfolio
By Mateen Dalal

South Korean consumer equipment firm, WAVE Electronics has recently formed an alliance with home automation company, Savant Systems, Inc. to provide CYNC™ smart home solutions to its contractors, custom installation professionals, and builders ...

WardWizard Innovations & Mobility to invest $20Mn in EV business
WardWizard Innovations & Mobility to invest $20Mn in EV business
By Mateen Dalal

Indian electric vehicle manufacturer, WardWizard Innovations and Mobility have expressed plans to spend INR 150 crore (USD 20 million) in the coming six months in its EV business, as it seeks to ramp up technology and infrastructure, among other thin...